Seeking Alpha


Send Message
View as an RSS Feed
View joenobody02's Comments BY TICKER:
Latest  |  Highest rated
  • Galena Biopharma: Numerous Red Flags Suggest A Significant Overvaluation [View article]
    The only thing that matters is outcome of the phase iii trial . We all agree the number of patients in the early trials are not large enough for a more definitive answer. The preliminary data is very suggestive and I would not dismiss it outright like the author did. The assertion that the 188 patients trial failed betray an ignorance of the phenomenon of "Immunological Tolerance" . This point has been raised before and am surprised it still resurface again and again. I doubt very much the FDA allows the phase iii to proceed if they do not see value in the subset of patients that show a response.
    The argument about patent protection is quite misleading. I think GALE stand a good chance of getting their new patent allowed. The non final rejection is very common. It just mean the patent as written is not completely satisfactory and they have a certain period of time to resubmit to either argue or compile. It is standard language, I got quite a number of those notices in the five patents I submitted (some granted). No one is in a position to steal the composition of matter patent from them because it " requires undue experimentation" for one to know if that composition of matter (the peptide) will work. The data from the clinical trials , may be including the phase iii ones will be the basis for their argument.
    Now, with all that said, I must agree I do not like the management. I lost quite a few spare changes in the early days of RXII and think to myself these guys do not play straight. However, at least these guys spend their time doing something productive and if they are successful they do deserve the reward. People shorting stocks are just scums for their activity does nothing other than benefiting themselves and in the process destroys companies bad or good.
    If you think I am writing this to promote GALE you are sorely mistaken. I like GNBT much more than GALE. I have sold off most of my GALE for a tidy profit and keep only a token 5000 shares just in case they are first to market.
    Feb 1 12:32 PM | 7 Likes Like |Link to Comment
  • Linn Energy LLC declares $0.2416 dividend [View news story]
    Barrons was anything but simple minded. It was used by shorts to bad mouth LINE for their own benefit. These are the nonproductive member of our world. They are unfortunately, also selfish and evil.
    Jan 31 03:49 AM | 5 Likes Like |Link to Comment
  • Small-cap biotechs scorched [View news story]
    ARNA is a monster in the making and is safer than most since its drug is already on the market.
    Jan 27 06:03 PM | Likes Like |Link to Comment
  • Small-cap biotechs scorched [View news story]
    I reduced my GALE position substantially. Holding the remaining shares just in case. Long term, GNBT has a better mouse trap.
    Jan 27 06:02 PM | Likes Like |Link to Comment
  • Zulauf pans China, likes gold and Treasurys [View news story]
    Hong Kong economy is heavily influenced by real estate. It is also a place where the mainlanders park their ill-gotten gains.
    Jan 18 04:44 PM | 1 Like Like |Link to Comment
  • Arena Pharmaceuticals - Why I Believe It Is The Next Major Biotech [View article]
    Great aarticle !
    However, the mention of ICPT in the same breath with ARNA does not seem warranted. Those who go long ICPT at this ridiculous level will end in tears, and very soon. Investment firm analyst will not be in the FDA panel, the liver experts will and they have a different idea of the end point they like to see.
    Jan 16 01:06 PM | Likes Like |Link to Comment
  • The Short Story Of Intercept Pharmaceuticals (Part I): A Conference Call With Expert Physicians [View article]
    Red flags all over this situation. I am amazed the stock has not already gone down to $7 a share. Are people " investing " or gambling ?
    Jan 14 02:33 PM | 1 Like Like |Link to Comment
  • Barron's: Wrong On MLPs Like Kinder Morgan Energy [View article]
    Barrons is now proven to be wrong about LINE. The SEC did not find anything worth pursuing despite Barrons unsubstantiated accusation. LINE 's future couldnt be better with its completion of acquisition of BRY.
    In my opinion, Barrons, in addition to being a bag-holders' bible, is transforming itself into a paradise of shorts bad mouthing.
    Jan 12 08:03 AM | 18 Likes Like |Link to Comment
  • Future Difficulties In Ultra-Deepwater Market Likely To Be Focused On Lower End [View article]
    Companies with older rigs should take out extra insurance on them and then set them on fire.
    Dec 18 02:10 AM | 3 Likes Like |Link to Comment
  • Bear Of The Day: Rentech Nitrogen [View article]
    If you are to buy more, why not write a 2015 put. A 2015 $37.5 put gets you $11.3 today and if it were put to you come 2015 January, you will have bought the shares at $26.4. If RNF runs past $37.5 by then, you will have made $11.3 . That is a annualized return of 18.1%.
    Apr 2 10:49 PM | 1 Like Like |Link to Comment
  • Deal Time for InterOil [View article]
    Are you aware that condensate is more valuable than crude ?
    Mar 17 02:22 PM | Likes Like |Link to Comment
  • Why Gold is Likely to Keep Moving Higher [View article]
    Gold is simply a form of currency. You cannot eat a gold coin nor a copper penny but they both have value. The value of the USD is backed by the promise of the US government. The value of gold is backed by its scarcity.
    Apr 10 08:41 AM | Likes Like |Link to Comment
  • When the Economy Hands You Lemons, Consider Dividend ETFs [View article]
    The 1 year return of RMB (i.e. CNY) is 11+%. You dont do anything and at almost no risk. Just exchange your sinking USD for the Chinese yuan and put it in an interest bearing 1 year saving deposit account.
    Apr 9 04:52 AM | Likes Like |Link to Comment
  • Changing of the Short Uptick Rule: Bad Timing for a Bad Idea [View article]
    Without the uptick rule in place, a hedge fund manager with enough "other peoples money" can kill a small company by selling short all the way to 25 cents if he wants(and profit handsomely). Biotech companies , for an example, are prime targets, a tiny bad news can drive the stock price to zero, depriving the drug that could have been developed.
    Mar 21 04:15 PM | 1 Like Like |Link to Comment